← Oncology Approval Tracker

FDA DECISION ·

Bortezomib Injection (Maia)

bortezomib · Maia Pharmaceuticals

FDA approvalNew formulationMultiple myeloma and mantle cell lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

An intravenous bortezomib injection product for adults with multiple myeloma or mantle cell lymphoma.

LAMPGEN ANALYSIS

Why it matters

The decision adds an IV presentation for two established hematology indications.

What research teams should watch

Keep the route and dose volume explicit to distinguish this product from formulations with other labeled administration options.

PRIMARY RECORDS

Sources